We have mentioned that IDH3α could promote the EMT by regulating the expression of glycolytic enzymes, and we found that IDH3α knockdown inhibited the resistance of tumor cells to cisplatin by inhibiting glycolysis-related enzymes and inducing ROS production. Here, IDH3A is linked to neoplasm.